Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma von Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Volltext

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer von Geukes Foppen, M.H., Donia, M., Svane, I.M., Haanen, J.B.A.G.

Volltext

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression von Scholtens, A, Geukes Foppen, M.H, Blank, C.U, van Thienen, J.V, van Tinteren, H, Haanen, J.B

Volltext

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma von Geukes Foppen, M.H., Brandsma, D., Blank, C.U., van Thienen, J.V., Haanen, J.B., Boogerd, W.

Volltext

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial von Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.

Volltext

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to s... von Rohaan, M.W., Borch, T.H., van den Berg, J.H., Geukes Foppen, M.H., Donia, M., Met, Ö, Nuijen, B., van Zon, M., Bakker, E.A.M., de Boer, R., Pronk, L.M., Wilgenhof, S., Blank, C.U., van Thienen, J.V., van Akkooi, A.C.J., Svane, I.-M., Haanen, J.B.A.G.

Volltext

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) von Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Volltext

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) von Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Volltext

Clinical aspects of immunotherapy and targeted therapy of advanced melanoma von Geukes Foppen, M.H.

Volltext bestellen

Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors von Abdel-Maksoud, Mohammed S., Ammar, Usama M., El-Gamal, Mohammed I., Gamal El-Din, Mahmoud M., Mersal, Karim I., Ali, Eslam M.H., Yoo, Kyung Ho, Lee, Kyung-Tae, Oh, Chang-Hyun

Volltext

Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma von van den Brom, Rob R. H., van der Geest, Kornelis S. M., Brouwer, Elisabeth, Hospers, Geke A. P., Boots, Annemieke M. H.

Volltext

Insights into Differentiation of Melanocytes from Human Stem Cells and Their Relevance for Melanoma Treatment von Mirea, Madalina, Eckensperger, Stefan, Hengstschläger, Markus, Mikula, Mario

Volltext

Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma von Kinslechner, Katharina, Schütz, Birgit, Pistek, Martina, Rapolter, Philipp, Weitzenböck, Hans P, Hundsberger, Harald, Mikulits, Wolfgang, Grillari, Johannes, Röhrl, Clemens, Hengstschläger, Markus, Stangl, Herbert, Mikula, Mario

Volltext

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma von George, Suzanne, Miao, Diana, Demetri, George D., Adeegbe, Dennis, Rodig, Scott J., Shukla, Sachet, Lipschitz, Mikel, Amin-Mansour, Ali, Raut, Chandrajit P., Carter, Scott L., Hammerman, Peter, Freeman, Gordon J., Wu, Catherine J., Ott, Patrick A., Wong, Kwok-Kin, Van Allen, Eliezer M.

Volltext

Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases von Tétu, Pauline, Sirven-Villaros, Lila, Cuzzubbo, Stefania, Ursu, Renata, Baroudjian, Barouyr, Delyon, Julie, Nataf, François, De Margerie-Mellon, Constance, Allayous, Clara, Lefevre, Wendy, Carpentier, Antoine F., Lebbé, Céleste

Volltext

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway von Wu, Pui-Kei, Becker, Andrew, Park, Jong-In

Volltext

Melanoma Brain Metastases in the Era of Target Therapies: An Overview von Becco, Paolo, Gallo, Susanna, Poletto, Stefano, Frascione, Mirko Pio Manlio, Crotto, Luca, Zaccagna, Alessandro, Paruzzo, Luca, Caravelli, Daniela, Carnevale-Schianca, Fabrizio, Aglietta, Massimo

Volltext

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges von Zhao, Yueshui, Deng, Jian, Rao, Shuangfeng, Guo, Sipeng, Shen, Jing, Du, Fukuan, Wu, Xu, Chen, Yu, Li, Mingxing, Chen, Meijuan, Li, Xiaobing, Li, Wanping, Gu, Li, Sun, Yuhong, Zhang, Zhuo, Wen, Qinglian, Xiao, Zhangang, Li, Jing

Volltext

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions von Proietti, Ilaria, Skroza, Nevena, Michelini, Simone, Mambrin, Alessandra, Balduzzi, Veronica, Bernardini, Nicoletta, Marchesiello, Anna, Tolino, Ersilia, Volpe, Salvatore, Maddalena, Patrizia, Di Fraia, Marco, Mangino, Giorgio, Romeo, Giovanna, Potenza, Concetta

Volltext

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells von Al Hmada, Youssef, Brodell, Robert T, Kharouf, Naji, Flanagan, Thomas W, Alamodi, Abdulhadi A, Hassan, Sofie-Yasmin, Shalaby, Hosam, Hassan, Sarah-Lilly, Haikel, Youssef, Megahed, Mosaad, Santourlidis, Simeon, Hassan, Mohamed

Volltext